Global Plasma Fractionation Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Plasma Fractionation Market:
Global plasma fractionation market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for plasma fractionation is projected to reach US$ XX Mn by 2023.
Plasma fractionation refers to the process of separation, extraction, and purification of plasma. Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and reduce the risks of viral transmissions.
Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.
Global plasma fractionation market segmented based on the product type, application, and end user
Based on product type, global plasma fractionation market segmented into the following:
Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.
Some of the players in plasma fractionation market are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France), and Sanquin (Netherlands) to name a few.
In 2017, Grifols opens new lines of research with the acquisition of a 44% stake in GigaGen for US$ 35Mn
In 2015, Baxalta receives CHMP positive opinion for sanquin to begin production, purification and enhancing global supply of plasma based therapies
In 2014, CSL Behring launched US$ 450 Mn capacity expansion to meet growing need for life-saving, and life improving therapies in plasma fractionation
REPORT OUTLINE:
Global plasma fractionation market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for plasma fractionation is projected to reach US$ XX Mn by 2023.
Plasma fractionation refers to the process of separation, extraction, and purification of plasma. Human plasma contains the large variety of proteins, however, only a few of these proteins are help in producing therapeutic plasma products. Plasma is used in prevention and treatment of various life threatening diseases caused by trauma, immunologic disorders, and infections. Plasma fractionation process is majorly used in treating protein deficiency condition in healthcare applications. The proteins extracted from the plasma are majorly categorized into three main classes: immunoglobulins which are useful in treatment of autoimmune disorders and increasing the immune response of the body, clotting factors which are help in treatment of blood disorders such as haemophilia, and the albumins which are useful in conditions of decreased albumin levels or during fluid loss. Plasma fractionation process is carried by different criteria such as solubility of the products, and their physical and chemical conditions such as ionic strengths, pH levels, and temperature, etc. The removal or inactivation of viruses and prions is an important function of plasma fractionation, and it can be carried by various mechanical and physical treatments for virus inactivation such as nano filtration, detergent/solvent treatment, heat treatment, chromatography centrifugation, ultrafiltration, and sterile filtration in order to achieve homogeneity of plasma, and reduce the risks of viral transmissions.
Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.
Global plasma fractionation market segmented based on the product type, application, and end user
Based on product type, global plasma fractionation market segmented into the following:
- Albumin
- Immunoglobulin
- Intravenous immunoglobulin
- Subcutaneous immunoglobulin
- Others
- Coagulation factor concentrates
- Factor viii
- Factor ix
- Factor xiii
- Prothrombin complex concentrates
- Von Willebrand factor (VWF)
- Protease inhibitors
- Other plasma fractionation products
- Neurology
- Haematology
- Immunology
- Rheumatology
- Haemato-oncology
- Critical Care
- Pulmonology
- Others
- Hospitals
- Clinics
- Academic Institutes
- Clinical Research Laboratories
Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.
Some of the players in plasma fractionation market are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France), and Sanquin (Netherlands) to name a few.
In 2017, Grifols opens new lines of research with the acquisition of a 44% stake in GigaGen for US$ 35Mn
In 2015, Baxalta receives CHMP positive opinion for sanquin to begin production, purification and enhancing global supply of plasma based therapies
In 2014, CSL Behring launched US$ 450 Mn capacity expansion to meet growing need for life-saving, and life improving therapies in plasma fractionation
REPORT OUTLINE:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenari
1. EXECUTIVE SUMMARY
2. GLOBAL PLASMA FRACTIONATION MARKET INTRODUCTION
2.1. Global Plasma Fractionation Market – Taxonomy
2.2. Global Plasma Fractionation Market – Definitions
2.2.1. Product Type
2.2.2. End User
3. GLOBAL PLASMA FRACTIONATION MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Plasma Fractionation Market Dynamics – Factors Impact Analysis
3.6. Global Plasma Fractionation Market– Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
4. GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Albumin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunoglobulins
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Coagulation factor concentrates
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Protease inhibitors
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Other Plasma Fractionation Products
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Neurology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hematology
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Immunology
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Rheumatology
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Haemato-oncology
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Critical Care
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Pulmonology
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Others
6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
7. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Academic Institutes
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Clinical Research Laboratories
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Region, 2017 – 2023
9. NORTH AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Albumin
9.1.1.2. Immunoglobulin
9.1.1.2.1. Intravenous immunoglobulin
9.1.1.2.2. Subcutaneous immunoglobulin
9.1.1.2.3. Others
9.1.1.3. Coagulation Factor Concentrates
9.1.1.3.1. Factor viii
9.1.1.3.2. Factor ix
9.1.1.3.3. Factor xiii
9.1.1.3.4. Prothrombin complex concentrates
9.1.1.3.5. Von Willebrand factor (VWF)
9.1.1.4. Protease Inhibitors
9.1.1.5. Other Plasma Fractionation Products
9.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Neurology
9.1.2.2. Hematology
9.1.2.3. Immunology
9.1.2.4. Rheumatology
9.1.2.5. Haemato-oncology
9.1.2.6. Critical Care
9.1.2.7. Pulmonology
9.1.2.8. Others
9.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospitals
9.1.3.2. Clinics
9.1.3.3. Academic Institutes
9.1.3.4. Clinical Research Laboratories
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023
9.1.6. North America Plasma Fractionation Market Dynamics – Trends
10. EUROPE PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Albumin
10.1.1.2. Immunoglobulin
10.1.1.2.1. Intravenous immunoglobulin
10.1.1.2.2. Subcutaneous immunoglobulin
10.1.1.2.3. Others
10.1.1.3. Coagulation Factor Concentrates
10.1.1.3.1. Factor viii
10.1.1.3.2. Factor ix
10.1.1.3.3. Factor xiii
10.1.1.3.4. Prothrombin complex concentrates
10.1.1.3.5. Von Willebrand factor (VWF)
10.1.1.4. Protease Inhibitors
10.1.1.5. Other Plasma Fractionation Products
10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Neurology
10.1.2.2. Hematology
10.1.2.3. Immunology
10.1.2.4. Rheumatology
10.1.2.5. Haemato-oncology
10.1.2.6. Critical Care
10.1.2.7. Pulmonology
10.1.2.8. Others
10.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospitals
10.1.3.2. Clinics
10.1.3.3. Academic Institutes
10.1.3.4. Clinical Research Laboratories
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
10.1.6. Europe Plasma Fractionation Market Dynamics – Trends
11. ASIA-PACIFIC PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Albumin
11.1.1.2. Immunoglobulin
11.1.1.2.1. Intravenous immunoglobulin
11.1.1.2.2. Subcutaneous immunoglobulin
11.1.1.2.3. Others
11.1.1.3. Coagulation Factor Concentrates
11.1.1.3.1. Factor viii
11.1.1.3.2. Factor ix
11.1.1.3.3. Factor xiii
11.1.1.3.4. Prothrombin complex concentrates
11.1.1.3.5. Von Willebrand factor (VWF)
11.1.1.4. Protease Inhibitors
11.1.1.5. Other Plasma Fractionation Products
11.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Neurology
11.1.2.2. Hematology
11.1.2.3. Immunology
11.1.2.4. Rheumatology
11.1.2.5. Haemato-oncology
11.1.2.6. Critical Care
11.1.2.7. Pulmonology
11.1.2.8. Others
11.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospitals
11.1.3.2. Clinics
11.1.3.3. Academic Institutes
11.1.3.4. Clinical Research Laboratories
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
11.1.6. Asia-Pacific Plasma Fractionation Market Dynamics – Trends
12. LATIN AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Albumin
12.1.1.2. Immunoglobulin
12.1.1.2.1. Intravenous immunoglobulin
12.1.1.2.2. Subcutaneous immunoglobulin
12.1.1.2.3. Others
12.1.1.3. Coagulation Factor Concentrates
12.1.1.3.1. Factor viii
12.1.1.3.2. Factor ix
12.1.1.3.3. Factor xiii
12.1.1.3.4. Prothrombin complex concentrates
12.1.1.3.5. Von Willebrand factor (VWF)
12.1.1.4. Protease Inhibitors
12.1.1.5. Other Plasma Fractionation Products
12.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Neurology
12.1.2.2. Hematology
12.1.2.3. Immunology
12.1.2.4. Rheumatology
12.1.2.5. Haemato-oncology
12.1.2.6. Critical Care
12.1.2.7. Pulmonology
12.1.2.8. Others
12.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospitals
12.1.3.2. Clinics
12.1.3.3. Academic Institutes
12.1.3.4. Clinical Research Laboratories
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
12.1.6. Latin America Plasma Fractionation Market Dynamics – Trends
13. MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Albumin
13.1.1.2. Immunoglobulin
13.1.1.2.1. Intravenous immunoglobulin
13.1.1.2.2. Subcutaneous immunoglobulin
13.1.1.2.3. Others
13.1.1.3. Coagulation Factor Concentrates
13.1.1.3.1. Factor viii
13.1.1.3.2. Factor ix
13.1.1.3.3. Factor xiii
13.1.1.3.4. Prothrombin complex concentrates
13.1.1.3.5. Von Willebrand factor (VWF)
13.1.1.4. Protease Inhibitors
13.1.1.5. Other Plasma Fractionation Products
13.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Neurology
13.1.2.2. Hematology
13.1.2.3. Immunology
13.1.2.4. Rheumatology
13.1.2.5. Haemato-oncology
13.1.2.6. Critical Care
13.1.2.7. Pulmonology
13.1.2.8. Others
13.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospitals
13.1.3.2. Clinics
13.1.3.3. Academic Institutes
13.1.3.4. Clinical Research Laboratories
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023
13.1.6. MEA Plasma Fractionation Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Grifols S.A (Spain)
14.2.2. CSL Ltd. (Australia)
14.2.3. Shire (Ireland)
14.2.4. Octapharma AG (Switzerland)
14.2.5. Kedrion S.p.A (Italy)
14.2.6. China Biologic Products, Inc. (China)
14.2.7. Biotest AG (OGEL GmbH) (Germany)
14.2.8. LFB S.A (France)
14.2.9. Sanquin (Netherlands)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL PLASMA FRACTIONATION MARKET INTRODUCTION
2.1. Global Plasma Fractionation Market – Taxonomy
2.2. Global Plasma Fractionation Market – Definitions
2.2.1. Product Type
2.2.2. End User
3. GLOBAL PLASMA FRACTIONATION MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Plasma Fractionation Market Dynamics – Factors Impact Analysis
3.6. Global Plasma Fractionation Market– Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
4. GLOBAL PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Albumin
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunoglobulins
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Coagulation factor concentrates
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Protease inhibitors
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Other Plasma Fractionation Products
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Neurology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hematology
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Immunology
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Rheumatology
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Haemato-oncology
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Critical Care
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Pulmonology
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Others
6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
7. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Academic Institutes
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Clinical Research Laboratories
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL PLASMA FRACTIONATION MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Region, 2017 – 2023
9. NORTH AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Albumin
9.1.1.2. Immunoglobulin
9.1.1.2.1. Intravenous immunoglobulin
9.1.1.2.2. Subcutaneous immunoglobulin
9.1.1.2.3. Others
9.1.1.3. Coagulation Factor Concentrates
9.1.1.3.1. Factor viii
9.1.1.3.2. Factor ix
9.1.1.3.3. Factor xiii
9.1.1.3.4. Prothrombin complex concentrates
9.1.1.3.5. Von Willebrand factor (VWF)
9.1.1.4. Protease Inhibitors
9.1.1.5. Other Plasma Fractionation Products
9.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Neurology
9.1.2.2. Hematology
9.1.2.3. Immunology
9.1.2.4. Rheumatology
9.1.2.5. Haemato-oncology
9.1.2.6. Critical Care
9.1.2.7. Pulmonology
9.1.2.8. Others
9.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospitals
9.1.3.2. Clinics
9.1.3.3. Academic Institutes
9.1.3.4. Clinical Research Laboratories
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023
9.1.6. North America Plasma Fractionation Market Dynamics – Trends
10. EUROPE PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Albumin
10.1.1.2. Immunoglobulin
10.1.1.2.1. Intravenous immunoglobulin
10.1.1.2.2. Subcutaneous immunoglobulin
10.1.1.2.3. Others
10.1.1.3. Coagulation Factor Concentrates
10.1.1.3.1. Factor viii
10.1.1.3.2. Factor ix
10.1.1.3.3. Factor xiii
10.1.1.3.4. Prothrombin complex concentrates
10.1.1.3.5. Von Willebrand factor (VWF)
10.1.1.4. Protease Inhibitors
10.1.1.5. Other Plasma Fractionation Products
10.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Neurology
10.1.2.2. Hematology
10.1.2.3. Immunology
10.1.2.4. Rheumatology
10.1.2.5. Haemato-oncology
10.1.2.6. Critical Care
10.1.2.7. Pulmonology
10.1.2.8. Others
10.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospitals
10.1.3.2. Clinics
10.1.3.3. Academic Institutes
10.1.3.4. Clinical Research Laboratories
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
10.1.6. Europe Plasma Fractionation Market Dynamics – Trends
11. ASIA-PACIFIC PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Albumin
11.1.1.2. Immunoglobulin
11.1.1.2.1. Intravenous immunoglobulin
11.1.1.2.2. Subcutaneous immunoglobulin
11.1.1.2.3. Others
11.1.1.3. Coagulation Factor Concentrates
11.1.1.3.1. Factor viii
11.1.1.3.2. Factor ix
11.1.1.3.3. Factor xiii
11.1.1.3.4. Prothrombin complex concentrates
11.1.1.3.5. Von Willebrand factor (VWF)
11.1.1.4. Protease Inhibitors
11.1.1.5. Other Plasma Fractionation Products
11.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Neurology
11.1.2.2. Hematology
11.1.2.3. Immunology
11.1.2.4. Rheumatology
11.1.2.5. Haemato-oncology
11.1.2.6. Critical Care
11.1.2.7. Pulmonology
11.1.2.8. Others
11.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospitals
11.1.3.2. Clinics
11.1.3.3. Academic Institutes
11.1.3.4. Clinical Research Laboratories
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
11.1.6. Asia-Pacific Plasma Fractionation Market Dynamics – Trends
12. LATIN AMERICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Albumin
12.1.1.2. Immunoglobulin
12.1.1.2.1. Intravenous immunoglobulin
12.1.1.2.2. Subcutaneous immunoglobulin
12.1.1.2.3. Others
12.1.1.3. Coagulation Factor Concentrates
12.1.1.3.1. Factor viii
12.1.1.3.2. Factor ix
12.1.1.3.3. Factor xiii
12.1.1.3.4. Prothrombin complex concentrates
12.1.1.3.5. Von Willebrand factor (VWF)
12.1.1.4. Protease Inhibitors
12.1.1.5. Other Plasma Fractionation Products
12.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Neurology
12.1.2.2. Hematology
12.1.2.3. Immunology
12.1.2.4. Rheumatology
12.1.2.5. Haemato-oncology
12.1.2.6. Critical Care
12.1.2.7. Pulmonology
12.1.2.8. Others
12.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospitals
12.1.3.2. Clinics
12.1.3.3. Academic Institutes
12.1.3.4. Clinical Research Laboratories
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user Type, and Country, 2017 – 2023
12.1.6. Latin America Plasma Fractionation Market Dynamics – Trends
13. MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Albumin
13.1.1.2. Immunoglobulin
13.1.1.2.1. Intravenous immunoglobulin
13.1.1.2.2. Subcutaneous immunoglobulin
13.1.1.2.3. Others
13.1.1.3. Coagulation Factor Concentrates
13.1.1.3.1. Factor viii
13.1.1.3.2. Factor ix
13.1.1.3.3. Factor xiii
13.1.1.3.4. Prothrombin complex concentrates
13.1.1.3.5. Von Willebrand factor (VWF)
13.1.1.4. Protease Inhibitors
13.1.1.5. Other Plasma Fractionation Products
13.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Neurology
13.1.2.2. Hematology
13.1.2.3. Immunology
13.1.2.4. Rheumatology
13.1.2.5. Haemato-oncology
13.1.2.6. Critical Care
13.1.2.7. Pulmonology
13.1.2.8. Others
13.1.3. End user Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospitals
13.1.3.2. Clinics
13.1.3.3. Academic Institutes
13.1.3.4. Clinical Research Laboratories
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Plasma Fractionation Market- Opportunity Analysis Index - By Product Type, By Application, By End user, and Country, 2017 – 2023
13.1.6. MEA Plasma Fractionation Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Grifols S.A (Spain)
14.2.2. CSL Ltd. (Australia)
14.2.3. Shire (Ireland)
14.2.4. Octapharma AG (Switzerland)
14.2.5. Kedrion S.p.A (Italy)
14.2.6. China Biologic Products, Inc. (China)
14.2.7. Biotest AG (OGEL GmbH) (Germany)
14.2.8. LFB S.A (France)
14.2.9. Sanquin (Netherlands)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
